Furthermore, a systematic review analyzed from data of randomized clinical trials also showed no statistically significant differences between IL-10 therapy and placebo for complete or clinical remission in Crohn’s disease, a type of IBD [48]. Here, IL10 is linked to inflammatory bowel disease.